Login or Register to unlock everything MedSchool has to offer!
Neuro Drugs


    IV / Oral
    Prednisolone / Prednisone
    Panafcort, Predsone, Sone 
    IV / IM / Oral
    Oral / IV / Local / Topical
    IV / Topical


    • Mechanism of Action

      Suppress the body's normal inflammatory response through:
    • Reduced monocyte recruitment
    • Suppression of arachidonic acid metabolites - prostaglandin, leukotriene, platelet-activating factor
    • Reduced production of interleukins, TNF-α, GM-CSF
    • Non-Inflammatory Effects of Corticosteroids

    • Increased circulating glucose - ↑gluconeogenesis, ↓glucose usage
    • Redistribution of fats - in face, neck, shoulder
    • ↓ Absorption of Ca²⁺
    • Muscle homeostasis

Clinical Use

    • Indications

    • Acute asthma
    • Exacerbations of COPD
    • Croup
    • Other inflammatory conditions - dermatitides, ulcerative colitis, autoimmune haemolytic anaemia, acute gout, rheumatoid arthritis, seronegative arthritides, systemic lupus erythematosus, polyarteritis nodosa
    • Cerebral oedema
    • Nephrotic syndrome
    • Replacement therapy for adrenocortical insufficiency
    • Immunosuppression post organ transplant
    • Adverse Effects

    • Immunosuppression (risk of infection)
    • Osteoporosis
    • Steroid-induced diabetes mellitus
    • Cushing’s - central obesity, ‘moon’ face, buffalo hump, thin skin, peripheral oedema, striae, bruising
    • CNS - cognitive impairment / emotional instability / fatigue
    • Renal - sodium & water retention / hypertension / oedema
    • GIT - peptic ulceration, nausea / vomiting
    • Muscle wasting
    • Ocular - cataract / glaucoma
    • Signs of Withdrawal

    • Worsening of underlying disease
    • Acute adrenal insufficiency
    • Raised ICP / papilloedema
    • Avoiding Withdrawal

    • Taper the dose by 2.5-5mg prednisone every 3-7 days prior to ceasing.
  • Give in the morning between 6-10am in order to mimic the normal diurnal cycle
Last updated on January 1st, 2017


The information in this section has been adapted in part from the Australian Therapeutic Goods Association website's repository of product information documents, which are available at https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI.
 Brodie MJ, Dichter MA. Antiepileptic drugs. N Engl J Med. 1996;334:168–175. Calm DB, Reid JL. Antiparkinsonian drugs: pharmacological and therapeutic aspects. Drugs. 1972 Jul 1;4(1-2):49-74. Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik I, et al. Levetiracetam for partial seizures. Results of a double-blind, randomized clinical trial. Neurology 2000;55:236-42 Fenstermacher, N, Levin, M and Ward, T. Pharmacological prevention of migraine. BMJ. 2011; 342: 540-543. Lawrence, ER, Hossain, M and Littlestone, W. Sanomigran for Migraine Prophylaxis; Controlled Multicenter Trial in General Practice. Headache. 1977; 17(3): 109-112.
Macdonald RL, McLean MJ. Anticonvulsant drugs: mechanisms of action. Advances in Neurology. 1986; 44: 713-736.
 Meldrum B, Mechanism of action of valproate. Brain Research Bulletin. 1980; 5(2 Suppl): 579-584. Nutt JG, Woodward WR, Anderson JL. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: The mechanism of action in the treatment of parkinsonism. Annals of Neurology. 1985 Nov; 18(5): 537–543. Piercey MF. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clinical neuropharmacology. 1998 May 1;21(3):141-51. Post RM, Weiss SR, Chuang DM. Mechanisms of action of anticonvulsants in affective disorders: comparisons with lithium. J Clin Psychopharmacol. 1992 Feb;12(1 Suppl): 23S-35S. Rudick RA, Goelz SE. Beta-Interferon for Multiple Sclerosis. Experimental Cell Research. 2011 May; 317(9): 1301-1311. Saxena, PR and Den Boer, MO. Pharmacology of antimigraine drugs. Journal of Neurology. 1991; 238: S28-S35. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000 Dec;60(6):1259.